Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents

Status unconfirmed

Conditions studied: Tardive Dyskinesia

In brief

Prospective study to quantify the prevalence of possible tardive dyskinesia (TD) in outpatient psychiatry practices in the United States (US), as well as to describe the associated disease burden in a cohort of patients with one or more psychiatric disorders and a cumulative lifetime exposure to antipsychotic medication of three months or more.

Key facts

Study ID

NCT03062033

Run by

Neurocrine Biosciences

People needed

70

Starts

2017-04-04

Expected to finish

2018-08-01

Last updated by the study team

2017-11-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient has a cumulative lifetime exposure to antipsychotic medication of three months or more
• Patient has a clinician confirmed diagnosis of one or more psychiatric disorder(s), as defined in the DSM-5
• Patient has a usual care clinic visit scheduled during the study recruitment window (i.e. a pre-defined 2-week period)
• Patient is able to read and understand English
• Patient is willing and able to comply with the study requirements

You may not qualify if…

• Patient is unable to provide informed consent.

Where it is running

• Neurocrine Clinical Site — Little Rock, Arkansas, United States (enrolling)
• Neurocrine Clinical Site — Anaheim, California, United States (enrolling)
• Neurocrine Clinical Site — Anaheim, California, United States (enrolling)
• Neurocrine Clinical Site — Long Beach, California, United States (enrolling)
• Neurocrine Clinical Site — Los Gatos, California, United States (enrolling)
• Neurocrine Clinical Site — Oceanside, California, United States (enrolling)
• Neurocrine Clinical Site — Gainesville, Florida, United States (enrolling)
• Neurocrine Clinical Site — Hialeah, Florida, United States (enrolling)
• Neurocrine Clinical Site — Jacksonville, Florida, United States (enrolling)
• Neurocrine Clinical Site — Miami, Florida, United States (enrolling)
• Neurocrine Clinical Site — Miami Beach, Florida, United States (enrolling)
• Neurocrine Clinical Site — Miami Springs, Florida, United States (enrolling)
• Neurocrine Clinical Site — North Miami, Florida, United States (enrolling)
• Neurocrine Clinical Site — Orlando, Florida, United States (enrolling)
• Neurocrine Clinical Site — Tampa, Florida, United States (enrolling)
• Neurocrine Clinical Site — Decatur, Georgia, United States (enrolling)
• Neurocrine Clinical Site — Honolulu, Hawaii, United States (enrolling)
• Neurocrine Clinical Site — Naperville, Illinois, United States (enrolling)
• Neurocrine Clinical Site — Michigan City, Indiana, United States (enrolling)
• Neurocrine Clinical Site — Grand Rapids, Michigan, United States (enrolling)
• Neurocrine Clinical Site — Rochester, Michigan, United States (enrolling)
• Neurocrine Clinical Site — Kansas City, Missouri, United States (enrolling)
• Neurocrine Clinical Site — St Louis, Missouri, United States (enrolling)
• Neurocrine Clinical Site — Lincoln, Nebraska, United States (enrolling)
• Neurocrine Clinical Site — Nashua, New Hampshire, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.